In ICI recipients, the negative association between ATB and survival outcomes was preserved across ICI monotherapy and combinations including dual PD-1/VEGF pathway blockade, the novel standard of care in advanced HCC.10 This evidence concerns the gene VEGFA and hepatocellular carcinoma.